Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales @ radiantinsights. com Web: http:// www. radiantinsights. com /
After nearly a decade of minimal progress in the development of hepatitis C therapies, the treatment landscape of hepatitis C has evolved substantially in recent years. This has resulted in an increasingly competitive market landscape, and several oral regimens that combine DAAs from different nonstructural( NS) HCV protein families- NS5B polymerase inhibitors, NS5A replication complex inhibitors and NS3 / 4A protease inhibitors- have already been licensed. These new combination therapies have been highly commercially successful and are now regarded as the gold-standard within the treatment algorithm.
Scope:
The escalating hepatitis C public healthcare need has resulted in a competitive market landscape
� What is the pathophysiology of hepatitis C?
� What are the common co-morbidities and complications?
� How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
� What are the most significant unmet needs within the market?
� The hepatitis C pipeline is relatively large and innovative
� Which molecule types and molecular targets are most prominent within the pipeline?
� Which first-in-class targets are most promising?
� How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
� The hepatitis C deals landscape is highly active
� Do hepatitis C products attract high deal values?
� Which molecule types and molecular targets dominate the deals landscape?
� Which first-in-class pipeline products have no prior involvement in licensing or codevelopment deals?
Request A Sample Copy Of This Report at: http:// www. radiantinsights. com / research / frontier-pharma-hepatitis-c / request-sample
First-in-class products account for a relatively small proportion of the hepatitis C pipeline. However, in comparison with historical hepatitis C trends, which saw virtually no first-in-class products approved over a large period up until 2011, the presence of a modest number of these products is promising. The first-in-class targets identified show considerable diversity, and the high number of novel pathways targeted by first-in-class products provides evidence of enhanced divergence in hepatitis C first-in-class innovation in recent years
https
:// www. facebook. com / RadiantInsights
https:// www. linkedin. com / company / radiant-insights https:// twitter. com / radiantinsights
https:// plus. google. com /+ Radiantinsights